Edwards Lifesciences stock slips 3.38% and underperforms rivals

8 articles · Updated · MarketWatch · May 8

Shares closed at $79.96 on Friday as the S&P 500 rose 0.84% to 7,398.93 and the Dow Jones Industrial Average added 0.02% to 49,609.16.
The decline marked Edwards' second straight daily loss, leaving the stock 9.02% below its 52-week high of $87.89 reached on 5 December.
Edwards lagged peers including Abbott, Medtronic and Stryker, while trading volume of 3.9 million shares was 1.2 million below its 50-day average.

After strong earnings and positive guidance, why are insiders selling millions in Edwards Lifesciences stock?

Is the market signaling deeper problems at Edwards Lifesciences that its stellar quarterly report failed to reveal?

As competitors dominate the new PFA heart market, is Edwards Lifesciences being left behind despite its TAVR leadership?